Article: 2-CdA has high long-term efficacy in hairy cell leukemia patients.

2004 OCT 27 - (NewsRx.com & NewsRx.net) -- 2-CdA has high long-term efficacy in hairy cell leukemia (HCL) patients.

Oncologists in Germany evaluated the "long-term results of both pretreated and previously untreated patients (pts)" with HCL "using uniformly a single 7-day course of 2-chlorodeoxyadenosine (2-CdA) by continuous infusion."

"In addition, the probability of obtaining another response with this drug in pts who relapsed after 2-CdA treatment" was determined, noted U. Jehn and coauthors at the University of Munich. "A total of 44 consecutive pts (34 males, 10 females) with a median age of 57 years (range 33-77) at the time of initiation of 2-CdA ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!